Cargando…

Identification of potential inhibitors of SARS-CoV-2 S protein–ACE2 interaction by in silico drug repurposing

Background: Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), a new coronavirus discovered that appeared in Wuhan, China, in December 2019, causes COVID-19 disease which have resulted in cases similar to SARS-atypical pneumonia. Worldwide, around 116 million cases and 2.57 million deaths...

Descripción completa

Detalles Bibliográficos
Autores principales:	Tristán-Flores, Fabiola E, Casique-Aguirre, Diana, Pliego-Arreaga, Raquel, Cervantes-Montelongo, Juan A, García-Gutierrez, Ponciano, Acosta-García, Gerardo, Silva-Martínez, Guillermo A
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	F1000 Research Limited 2021
Materias:	Research Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8630554/ https://www.ncbi.nlm.nih.gov/pubmed/34900223 http://dx.doi.org/10.12688/f1000research.52168.2

Ejemplares similares

SARS-CoV-2 entry inhibitors by dual targeting TMPRSS2 and ACE2: An in silico drug repurposing study
por: Baby, Krishnaprasad, et al.
Publicado: (2021)

In silico screening of known small molecules to bind ACE2 specific RBD on Spike glycoprotein of SARS-CoV-2 for repurposing against COVID-19
por: BR, Bharath, et al.
Publicado: (2020)

In silico study of intrinsic dynamics of full-length apo-ACE2 and RBD-ACE2 complex
por: Liu, Qing, et al.
Publicado: (2021)

The Repurposed ACE2 Inhibitors: SARS-CoV-2 Entry Blockers of Covid-19
por: Ahmad, Iqrar, et al.
Publicado: (2021)

Albendazole repurposing on VEGFR-2 for possible anticancer application: In-silico analysis
por: Gaikwad, Nikita Maruti, et al.
Publicado: (2023)

Quinolines-Based SARS-CoV-2 3CLpro and RdRp Inhibitors and Spike-RBD-ACE2 Inhibitor for Drug-Repurposing Against COVID-19: An in silico Analysis
por: Alexpandi, Rajaiah, et al.
Publicado: (2020)

In vitro and in silico evaluation of antiretrovirals against SARS-CoV-2: A drug repurposing approach
por: Zapata-Cardona, Maria I., et al.
Publicado: (2023)

Investigating the ACE2 polymorphisms in COVID‐19 susceptibility: An in silico analysis
por: Pouladi, Nasser, et al.
Publicado: (2021)

In silico repurposing of antipsychotic drugs for Alzheimer’s disease
por: Kumar, Shivani, et al.
Publicado: (2017)

In Silico Repurposed Drugs against Monkeypox Virus
por: Lam, Hilbert Yuen In, et al.
Publicado: (2022)

SARS CoV-2 Spike Protein in silico Interaction With ACE2 Receptors From Wild and Domestic Species
por: Rendon-Marin, Santiago, et al.
Publicado: (2021)

Drug Repurposing Against Angiotensin-Converting Enzyme-Related Carboxypeptidase (ACE2) Through Computational Approach
por: Vaseghi, Golnaz, et al.
Publicado: (2022)

Intussusception and SARS-CoV-2 infection
por: Mercado-Martínez, Israel, et al.
Publicado: (2021)

In Silico Drug Repurposing for SARS-CoV-2 Main Proteinase and Spike Proteins
por: Maffucci, Irene, et al.
Publicado: (2020)

In Vitro Evaluation of In Silico Screening Approaches in Search for Selective ACE2 Binding Chemical Probes
por: Rayevsky, Alexey V., et al.
Publicado: (2022)

ACE2 and Diabetes: ACE of ACEs?
por: Batlle, Daniel, et al.
Publicado: (2010)

On the Integration of In Silico Drug Design Methods for Drug Repurposing
por: March-Vila, Eric, et al.
Publicado: (2017)

Calcium Signaling Pathway Is Involved in the Shedding of ACE2 Catalytic Ectodomain: New Insights for Clinical and Therapeutic Applications of ACE2 for COVID-19
por: García-Escobar, Artemio, et al.
Publicado: (2022)

A Repurposed Drug Screen Identifies Compounds That Inhibit the Binding of the COVID-19 Spike Protein to ACE2
por: Tsegay, Kaleb B., et al.
Publicado: (2021)

In silico drug repurposing for coronavirus (COVID-19): screening known HCV drugs against the SARS-CoV-2 spike protein bound to angiotensin-converting enzyme 2 (ACE2) (6M0J)
por: Kalamatianos, Konstantinos G.
Publicado: (2022)

Prediction of ACE-I Inhibitory Peptides Derived from Chickpea (Cicer arietinum L.): In Silico Assessments Using Simulated Enzymatic Hydrolysis, Molecular Docking and ADMET Evaluation
por: Arámburo-Gálvez, Jesús Gilberto, et al.
Publicado: (2022)

In silico Guided Drug Repurposing: Discovery of New Competitive and Non-competitive Inhibitors of Falcipain-2
por: Alberca, Lucas N., et al.
Publicado: (2019)

In-Silico targeting of SARS-CoV-2 NSP6 for drug and natural products repurposing
por: Abdelkader, Ahmed, et al.
Publicado: (2022)

Repurposing Astragalus Polysaccharide PG2 for Inhibiting ACE2 and SARS-CoV-2 Spike Syncytial Formation and Anti-Inflammatory Effects
por: Lee, Chia-Yin, et al.
Publicado: (2023)

Repurposing FDA-approved drugs for SARS-CoV-2 through an ELISA-based screening for the inhibition of RBD/ACE2 interaction
por: Fu, Wenyu, et al.
Publicado: (2020)

Role of ACE2 receptor and the landscape of treatment options from convalescent plasma therapy to the drug repurposing in COVID-19
por: Kumar, Pravindra, et al.
Publicado: (2020)

ACE2 Netlas: In-silico functional characterization and drug-gene interactions of ACE2 gene network to understand its potential involvement in COVID-19 susceptibility
por: Pathak, Gita A, et al.
Publicado: (2020)

ACE2 Netlas: In silico Functional Characterization and Drug-Gene Interactions of ACE2 Gene Network to Understand Its Potential Involvement in COVID-19 Susceptibility
por: Pathak, Gita A., et al.
Publicado: (2021)

Angiotensin-converting enzymes (ACE, ACE2) gene variants and COVID-19 outcome
por: Gómez, Juan, et al.
Publicado: (2020)

In silico analysis of ACE2 from different animal species provides new insights into SARS-CoV-2 species spillover
por: Mesquita, Felipe Pantoja, et al.
Publicado: (2023)

Evaluation of Inhibitory Activity In Silico of In-House Thiomorpholine Compounds between the ACE2 Receptor and S1 Subunit of SARS-CoV-2 Spike
por: Vázquez-Valadez, Victor H., et al.
Publicado: (2021)

In Silico Screening of Potential Spike Glycoprotein Inhibitors of SARS-CoV-2 with Drug Repurposing Strategy
por: Wei, Tian-zi, et al.
Publicado: (2020)

Repurposing FDA-approved drugs against multiple proteins of SARS-CoV-2: An in silico study
por: Akinlalu, Alfred Olaoluwa, et al.
Publicado: (2021)

Repurposing of Doxycycline to Hinder the Viral Replication of SARS-CoV-2: From in silico to in vitro Validation
por: Alexpandi, Rajaiah, et al.
Publicado: (2022)

Molecular docking suggests repurposing of brincidofovir as a potential drug targeting SARS-CoV-2 ACE2 receptor and main protease
por: Hussien, Mostafa A., et al.
Publicado: (2020)

Comprehensive in silico identification of impacts of ACE2 SNPs on COVID-19 susceptibility in different populations
por: Paniri, Alireza, et al.
Publicado: (2021)

In Vitro and Silico Studies on the N-Doped Carbon Dots Potential in ACE2 Expression Modulation
por: Mailisa, Wiska, et al.
Publicado: (2023)

In Silico Studies of Some Isoflavonoids as Potential Candidates against COVID-19 Targeting Human ACE2 (hACE2) and Viral Main Protease (M(pro))
por: Alesawy, Mohamed S., et al.
Publicado: (2021)

Effect of age on human ACE2 and ACE2-expressing alveolar type II cells levels
por: Silva, Mauro G., et al.
Publicado: (2022)

Repurposing of existing FDA approved drugs for Neprilysin inhibition: An in-silico study
por: Sankhe, Runali, et al.
Publicado: (2021)

Cannot write session to /tmp/vufind_sessions/sess_tu1oji2emmrr2mt041jpgu20q0